RA Capital Management’s Astria Therapeutics ATXS Stock Holding History

RA Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,105,213	Closed	-$27.3M	–	67
2025 Q1	$27.3M	Hold	5,105,213	–	–	0.46%	34
2024 Q4	$45.6M	Hold	5,105,213	–	–	0.61%	35
2024 Q3	$56.2M	Buy	5,105,213 +61,457	+1%	+$683K	0.65%	34
2024 Q2	$45.9M	Buy	5,043,756 +630,606	+14%	+$6.16M	0.61%	40
2024 Q1	$62.1M	Buy	+4,413,150	New	+$55M	0.79%	34
2022 Q3	–	Sell	-760,857	Closed	-$2.28M	–	83
2022 Q2	$2.28M	Sell	760,857 -501,336	-40%	-$2.25M	0.06%	78
2022 Q1	$8.47M	Hold	1,262,193	–	–	0.18%	81
2021 Q4	$6.8M	Hold	1,262,193	–	–	0.12%	89
2021 Q3	$11.2M	Buy	1,262,193 +270,883	+27%	+$2.6M	0.15%	71
2021 Q2	$12.6M	Buy	+991,310	New	+$12.9M	0.2%	66

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RA Capital Management's ATXS Position: Q2 2025 in Review

RA Capital Management sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 5,105,213 shares — an estimated $27.3M sold.

RA Capital Management first reported a position in ATXS in Q2 2021 and held it in 10 quarters. The position peaked at $62.1M in Q1 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

RA Capital Management reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
RA Capital Management sold 5,105,213 Astria Therapeutics shares in Q2 2025, an estimated $27.3M.
RA Capital Management first reported a position in Astria Therapeutics in Q2 2021 and held it in 10 quarters.
RA Capital Management's Astria Therapeutics position peaked at $62.1M in Q1 2024.
105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on RA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.